Company profile for Astraea Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Founded in 2008, Astraea Therapeutics is a privately-held biopharmaceutical company, specializing in novel approaches, with small-molecule therapeutics, for the treatment of drug addiction and central nervous system disorders, including pain and neurodegenerative diseases. Astraea’s core competencies in innovative drug discovery result from deep, long-standing expertise in novel target validation, creation of new molecular ...
Founded in 2008, Astraea Therapeutics is a privately-held biopharmaceutical company, specializing in novel approaches, with small-molecule therapeutics, for the treatment of drug addiction and central nervous system disorders, including pain and neurodegenerative diseases. Astraea’s core competencies in innovative drug discovery result from deep, long-standing expertise in novel target validation, creation of new molecular entities and intellectual property, well-defined translational development, and a mission to develop life-changing medications for unmet needs in CNS disorders.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
320 Logue Avenue Mountain View, CA 94043
Telephone
Telephone
650-254-0786
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Clinical Outsourcing

Clinical Outsourcing

Not Confirmed

envelop Contact Supplier

Clinical Outsourcing

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
FDA clears AZ’s new PNH therapy Voydeya
FDA clears AZ’s new PNH therapy Voydeya

01 Apr 2024

// PRESS RELEASE

https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-approved-in-us.html#:~:text=Voydeya%20is%20a%20first%2Din,treated%20with%20a%20C5%20inhibitor.

PRESS RELEASE
01 Apr 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty